Contrasting TNF Pharmaceuticals (NASDAQ:TNFA) and ARS Pharmaceuticals (NASDAQ:SPRY)

ARS Pharmaceuticals (NASDAQ:SPRY) and TNF Pharmaceuticals (NASDAQ:TNFA) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, dividends, risk, valuation, profitability, analyst recommendations and institutional ownership.

Volatility and Risk

ARS Pharmaceuticals has a beta of 0.95, suggesting that its stock price is 5% less volatile than the S&P 500. Comparatively, TNF Pharmaceuticals has a beta of 2.04, suggesting that its stock price is 104% more volatile than the S&P 500.

Insider and Institutional Ownership

68.2% of ARS Pharmaceuticals shares are held by institutional investors. Comparatively, 9.6% of TNF Pharmaceuticals shares are held by institutional investors. 33.8% of ARS Pharmaceuticals shares are held by company insiders. Comparatively, 0.4% of TNF Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Profitability

This table compares ARS Pharmaceuticals and TNF Pharmaceuticals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
ARS Pharmaceuticals	-200.00%	-153.61%	-60.85%
TNF Pharmaceuticals	N/A	-69.21%	-33.98%

Earnings & Valuation

This table compares ARS Pharmaceuticals and TNF Pharmaceuticals”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ARS Pharmaceuticals	$84.28 million	10.09	-$171.30 million	($2.01)	-4.26
TNF Pharmaceuticals	N/A	N/A	-$23.36 million	($231.00)	-0.02

TNF Pharmaceuticals has lower revenue, but higher earnings than ARS Pharmaceuticals. ARS Pharmaceuticals is trading at a lower price-to-earnings ratio than TNF Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of current ratings and target prices for ARS Pharmaceuticals and TNF Pharmaceuticals, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ARS Pharmaceuticals	1	1	4	0	2.50
TNF Pharmaceuticals	1	0	0	0	1.00

ARS Pharmaceuticals presently has a consensus target price of $28.20, indicating a potential upside of 229.44%. Given ARS Pharmaceuticals’ stronger consensus rating and higher probable upside, research analysts clearly believe ARS Pharmaceuticals is more favorable than TNF Pharmaceuticals.

Summary

ARS Pharmaceuticals beats TNF Pharmaceuticals on 7 of the 13 factors compared between the two stocks.

About ARS Pharmaceuticals

ARS Pharmaceuticals, Inc., a biopharmaceutical company, develops treatments for severe allergic reactions. The company is developing neffy, a needle-free and low-dose intranasal epinephrine nasal spray for the emergency treatment of Type I allergic reactions, including anaphylaxis. It serves healthcare professionals, patients, and caregivers. ARS Pharmaceuticals, Inc. was founded in 2015 and is headquartered in San Diego, California.

About TNF Pharmaceuticals

TNF Pharmaceuticals, Inc. operates as a clinical stage pharmaceutical company. It focuses on developing two novel therapeutic platforms that treat the causes of disease rather than addressing the symptoms. Its MYMD-1 is a drug platform based on a clinical stage small molecule that regulates the immune system to control TNF-a, which drives chronic inflammation, and other pro-inflammatory cell signaling cytokines. The MYMD-1 is being developed to delay aging, increase longevity, and treat autoimmune diseases. The company’s second drug platform, Supera-CBD, is being developed to treat chronic pain, addiction, and epilepsy. The Supera-CBD is a novel synthetic derivative of cannabidiol (CBD) and is being developed to address and improve the growing CBD market, which includes FDA approved drugs and CBD products not regulated as drugs. TNF Pharmaceuticals, Inc. was formerly known as MyMD Pharmaceuticals, Inc. and changed its name to TNF Pharmaceuticals, Inc. in July 2024. The company was founded in 2014 and is headquartered in Baltimore, Maryland.